A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes ( FABULINUS ): Rationale and Study Design

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes ( FABULINUS ): Rationale and Study Design | ReachRx